- Effects of Naloxegol on Gastrointestinal Transit and Colonic Fecal Volume in Healthy Participants Receiving Oxycodone
-
Olesen AE, Grønlund , Mark EB, Krogh K, Frøkjær , Drewes AM
- KMID: 2460489
- J Neurogastroenterol Motil.
- 2019 Oct;25(4):602-610.
- doi: 10.5056/jnm18079
BACKGROUND/AIMS: Opioids cause gastrointestinal (GI) dysmotility, decrease gut secretion, and affect gut sphincters. Symptoms of opioid-induced bowel dysfunction may be alleviated by peripherally acting opioid antagonists like naloxegol, but detailed... -
- CITED
-
- Close
- SHARE
-
- Close
- Gastric Emptying Time and Volume of the Small Intestine as Objective Markers in Patients With Symptoms of Diabetic Enteropathy
-
Klinge MW, Sutter N, Mark EB, Haase AM, Borghammer P, Schlageter V, Lund S, Fleischer J, Knudsen K, Drewes AM, Krogh K
- KMID: 2517533
- J Neurogastroenterol Motil.
- 2021 Jul;27(3):390-399.
- doi: 10.5056/jnm19195
Background/Aims Patients with diabetes mellitus (DM) often suffer from gastrointestinal (GI) symptoms, but these correlate poorly to established objective GI motility measures. Our aim is to perform a detailed evaluation of... -
- CITED
-
- Close
- SHARE
-
- Close
- Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
-
Poulsen JL, Mark EB, Brock C, Frøkjær , Krogh K, Drewes AM
- KMID: 2417279
- J Neurogastroenterol Motil.
- 2018 Jan;24(1):119-127.
- doi: 10.5056/jnm17058
BACKGROUND/AIMS: Opioid-induced constipation (OIC) is the most common gastrointestinal (GI) side effect to opioid treatment. Opioid receptor antagonists against OIC have been introduced, but their efficacy has not been directly... -
- CITED
-
- Close
- SHARE
-
- Close
